PhaseBio Pharmaceuticals Inc
PHASDelisted Dec 21, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001169245
PhaseBio Pharmaceuticals Inc was delisted on Dec 21, 2022; its insiders filed their last Form 4 on May 19, 2023; 39 institutions reported holding it in 13F filings for Q3 2022, worth $3.90M in total; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 39
- Q3 2022, −11 vs. previous quarter
- 13F value
- $3.90M
- Reported value at the end of Q3 2022
- Superinvestors holding
- 0
- At the end of Q3 2022
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2021
- $10.8M
- +3,284.7% year over year
- Net income, FY2021
- -$131.1M
- No comparable prior period
- Free cash flow, FY2021
- -$50.1M
- No comparable prior period
- Revenue, Q2 FY2022
- $208.0K
- −98.0% year over year
Revenue flow, FY2021
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2021: $131.1M (1210.1% of revenue).
Superinvestors holding PHAS, Q3 2022
Go to the superinvestors tabNo superinvestor reported holding PHAS at the end of Q3 2022.
Latest insider trades
See all insider tradesOpen-market purchases and sales by PhaseBio Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 26, 2022 (view filing)4:41 PM ET | Oct 25 | 1 day | Kerins Patrick J and 5 others10% Owner | SSale | −1.78M | $0.147 | −$262.3K | −26.9%4.86M after | |
| May 24, 2022 (view filing) | May 23 | 1 day | Burkhardt GlenSVP of Human Resources | SSale | −11.2K | $0.79 | −$8.89K | −100.0%0 after | |
| May 20, 2022 (view filing) | Aug 18, 2021 | 275 days | Hutson Nancy JDirector | PPurchase | +3.00K | $3.08 | +$9.24K | +300.0%4.00K after | Amended |
| Nov 23, 2021 (view filing) | Nov 19 | 4 days | Burkhardt GlenVP, Human Resources | SSale | −5.77K | $2.37 | −$13.7K | −100.0%0 after | |
| Aug 18, 2021 (view filing) | Aug 18 | Same day | Thorp ClayDirector | PPurchase | +10.0K | $3.00 | +$30.0K | +43.6%32.9K after |
Top 10 13F holders, Q3 2022
See all 39 holdersThe largest institutional positions in PhaseBio Pharmaceuticals Inc at the end of Q3 2022; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 6,643,702 | $1.17M | 0.06% | 00.0% | Unchanged |
| Avidity Partners Management LP | 4,361,365 | $768.0K | 0.02% | −43,635−1.0% | Reduced |
| Rock Springs Capital Management LP | 2,719,074 | $479.0K | 0.01% | −55,795−2.0% | Reduced |
| MAI Capital Management | 2,307,534 | $406.0K | 0.01% | +598,430+35.0% | Added |
| Vanguard Group Inc | 1,808,098 | $318.0K | 0.00% | 00.0% | Unchanged |
| Johnson & Johnson | 1,607,044 | $283.0K | 0.08% | 00.0% | Unchanged |
| BlackRock Inc. | 665,563 | $116.0K | 0.00% | −18,641−2.7% | Reduced |
| DAFNA Capital Management LLC | 321,856 | $57.0K | 0.02% | −56,755−15.0% | Reduced |
| Geode Capital Management, LLC | 320,642 | $56.0K | 0.00% | 00.0% | Unchanged |
| Platform Technology Partners | 231,900 | $41.0K | 0.02% | −11,000−4.5% | Reduced |